COMPANY PROFILE

Biosight

Explore full profile

Innovative therapeutics for safer, more effective cancer treatment, improving patient outcomes and quality of life

Lod, IsraelFounded 2000Biotech & Life Sciences

Valuation $100–250M Last recorded · 2020

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Biosight

Biosight Pharma is a private, clinical-stage biotech company focused on developing innovative therapeutics for hematological malignancies and disorders. The company primarily serves patients with life-threatening diseases such as acute myeloid leukemia (AML), particularly targeting older patients who are unfit for standard chemotherapy. Operating in the oncology and hematology markets, Biosight Pharma's business model revolves around the research, development, and clinical trials of novel drug candidates. The company's lead product, BST-236 (aspacytarabine), is an advanced anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity, aiming to provide safer and more effective treatment options. Revenue generation is expected through the successful commercialization of its drug candidates, either independently or through partnerships with larger pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2000
Headquarters: Lod, Israel
Employees: 3
Open positions: None listed
Dealroom signal: 63.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Developer Tools, Biotechnology, Oncology, Chemotherapy, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Oct 2023	$0	—	Ayala Pharmaceuticals	↗
SERIES COther financing	Dec 2020	$27M	$108M	Arkin Capital · Primera Capital · Migdal Insurance and Financial Holdings · The Phoenix Company	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Biosight website traffic

Latest recorded traffic for Biosight is 1.4K monthly website visits, up 84.2% over the last three months. Biosight's team declined 62.5% over the past year.

Latest monthly visits1.4K 3-month web change+84.2% 1-year team growth-62.5%

Monthly website visitsJan 2016–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CPCorvus PharmaceuticalsClinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer	Burlingame, United States	Operational	53	$109M	$1B
TPTCD PharmaTCD Pharma is a biotechnology company engaged in the discovery, development and commercialization of oncology drugs.	Valladolid, Spain	Operational
CTCytori TherapeuticsInnovative medical devices and cell therapy solutions enhancing patient health and well-being globally	San Diego, United States	Operational
ESEOS (Ethical Oncology Science)Biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.	Milan, Italy	Acquired
SISilenseedRNAi-based cancer drugs with proprietary delivery system	Modi'in-Maccabim-Re'ut, Israel	Operational
RBRedHill BiopharmaRedHill (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on proprietary drugs for gastrointestinal diseases	Raleigh, United States	Operational
CBCan-Fite BioPharmaA biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities	Petah Tikva, Israel	Operational
BEBerGenBioLeader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance	Bergen, Norway	Acquired